

1. A method for treating proliferative skin diseases comprising the administration of an effective amount of tazarotene and an effective amount of a corticosteroid.

5

2. The method of claim 1 wherein said corticosteroid is selected from the group consisting of fluocinolone acetonide, mometasone furoate, fluocinonide, diflorasone diacetate, fluticasone propionate, betamethasone dipropionate, clobetasol propionate, betamethasone valerate.

10

3. The method of claim 1 wherein tazarotene is applied as a 0.1% gel.

4. The method of claim 1 wherein said corticosteroid is a mid- or high-potency corticosteroid.

15

5. The method of claim 4 wherein said corticosteroid is selected from the group consisting of mometasone furoate and fluocinolone acetonide.

20

6. A method for treating psoriasis in a human subject by topically applying to the psoriatic skin of said subject an effective amount of tazarotene and an effective amount of a corticosteroid.

7. The method of claim 6 wherein tazarotene is applied as a 0.1% gel.

25

8. The method of claim 7 wherein said corticosteroid is a cream.

9. The method of claim 8 wherein said corticosteroid is a mid- or high-potency corticosteroid.

10. The method of claim 9 wherein said corticosteroid is selected from the group consisting of mometasone furoate and fluocinolone.

11. The method of claim 6 wherein tazarotene is administered once
5 daily in the evening and the corticosteroid is administered once daily in the morning.